Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...

The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...

A Novartis drug has been shown to reduce risk of disability progression in secondary progressive multiple sclerosis, an advanced form of the disease. The Swiss pharma said the phase 3 EXPAND study ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

an MS researcher at the National Institutes of Health. Novartis plans to file for US Food and Drug Administration registration in late 2009, although Kaplan thinks that date may be pushed back ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Sanofi's Mixed Fortunes in MS Drug Trials Has Market Focus ... but safety concerns also emerged last November. Rival Novartis has said its BTK drug candidate had shown no signs of liver damage.

Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, fo ...

The same device technology is also used in Novartis’ fast-growing multiple sclerosis drug Kesimpta. Pharma companies have been keen on developing subcutaneous injectables for IV medicines.